ResMed (RMD) Misses Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $221.05 -3.2%
EPS Growth %: +5.5%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $1.47, $0.05 worse than the analyst estimate of $1.52. Revenue for the quarter came in at $894.9 million versus the consensus estimate of $935.3 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Barnes & Noble Education (BNED) Tops Q1 EPS by 12c
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
